Showing results (531-540 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|October 18, 2013
Economic burden of cancer across the European Union: a population-based cost analysisRamon Luengo-Fernandez, Jose Leal, Alastair Gray, et al.
The Lancet. Oncology|August 23, 2013
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyXavier Pivot, Joseph Gligorov, Volkmar Müller, et al.
The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
The Lancet. Oncology|July 3, 2013
Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic reviewDaniel C Bowers, Paul C Nathan, Louis Constine, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
The Lancet. Oncology|March 3, 2012
Breast cancer in Brazil: present status and future goalsBrittany L Lee, Pedro Er Liedke, Carlos H Barrios, et al.
The Lancet. Oncology|October 11, 2011
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysisMary Eapen, John P Klein, Guillermo F Sanz, et al.
The Lancet. Oncology|December 24, 2011
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyWalter H Gotlieb, Frederic Amant, Suresh Advani, et al.
Pageof 336